Clinical trials: Advanced Urothelial Carcinoma
Bladder Carcinoma
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study
- Trial name
- ARCADIA (NCT03824691)
- Testing
- Cabozantinib, Durvalumab
- Where
- Italy
- Volunteers
- 122 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Urothelial Carcinoma
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
The purpose of this study is to test the safety and effectiveness of immunotherapy (checkpoint inhibitor therapy) in advanced bladder cancer when given intermittently.
- Trial name
- NCT04322643
- Testing
- Pembrolizumab, Atezolizumab, Durvalumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006026
- Testing
- rubitecan
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 21 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Urothelial Carcinoma
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to have surgery to remove their…
- Trial name
- NCT05239624
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer, Ureter Cancer
Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum
Taxane-based chemotherapy is currently one of the most commonly used regimen for salvage chemotherapy in advanced urothelial carcinoma.
- Trial name
- NCT01426126
- Testing
- Genexol PM
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Asan Medical Center
Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A in solid tumors included the dose escalation phase for evaluating the safety and tolerability profile of…
- Trial name
- NCT02608125
- Testing
- PRN1371
- Where
- 12 sites in United States, Spain
- Volunteers
- 45 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Urothelial Carcinoma
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
This study is a multicenter, non-interventional, retrospective, medical chart review of locally advanced or metastatic (la/m) Urothelial Cancer UC participants who were prescribed avelumab as first line maintenance therapy after…
- Trial name
- NCT06412848
- Testing
- Avelumab
- Where
- 26 sites in Japan
- Volunteers
- 360 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
- Trial name
- NCT04879329
- Testing
- disitamab vedotin, pembrolizumab
- Where
- 221 sites in United States, Argentina and 10 more
- Volunteers
- 372 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Urothelial Carcinoma (UC)
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.
- Trial name
- NCT07636772
- Testing
- AK146D1 for injection, AK112 Injection
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Akeso
Urothelial Carcinoma
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
In this phase II multicenter study, the investigators aim to evaluate the efficacy and tolerability of a novel taxane-cabazitaxel as single agent second-line chemotherapy for metastatic urothelial carcinoma.
- Trial name
- NCT01600339
- Testing
- CABAZITAXEL
- Where
- 2 sites in Israel
- Volunteers
- 19 people
- Sponsor
- Rambam Health Care Campus
Bladder Cancer
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with…
- Trial name
- NCT07232602
- Testing
- MK-3120, EV, Pembrolizumab
- Where
- 17 sites in United States, Chile and 6 more
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Gastric Cancer
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05867121
- Testing
- RO7496353, Atezolizumab, Capecitabine
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Urologic Neoplasms
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
- Trial name
- NCT00034593
- Testing
- ALIMTA, gemcitabine
- Where
- 9 sites in Finland, France and 1 more
- Sponsor
- Eli Lilly and Company
Urothelial Cancer
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
The purpose of this study is to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease.
- Trial name
- NCT02033993
- Testing
- Nab-Paclitaxel, Paclitaxel
- Where
- 37 sites in Australia, Canada
- Volunteers
- 199 people
- Sponsor
- Canadian Cancer Trials Group
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or…
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- NCT06524544
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 162 sites in United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
This is an open-label, switch maintenance study of MRx0518 and Avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) whose disease did not progress after 4 to 6 cycles of first-line…
- Trial name
- AVENU (NCT05107427)
- Testing
- MRx0518, Avelumab 20 mg/mL Intravenous Solution (IV)
- Where
- 3 sites in United States
- Sponsor
- 4D pharma plc
Transitional Cell Carcinoma of Bladder
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Salvage chemotherapy for advanced urothelial cancer (UC) yields suboptimal response rates of 15-40%, a median progression-free survival of 2-4 months and a median overall survival of 6 months.
- Trial name
- NCT01620970
- Testing
- PF03446962
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Urothelial Carcinoma, Probiotics
Probiotics in Advanced Urothelial Carcinoma
This is a multicenter, randomized, controlled phase II Study of evaluating the efficacy and safety of immunotherapy combined with probiotics compound (Biolosion) in patients with advanced urothelial carcinoma.
- Conditions
- Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
- Trial name
- IMPROVE (NCT06904573)
- Testing
- Probiotics Compound (Biolosion), Nab-paclitaxel, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 222 people
- Sponsor
- Sun Yat-sen University